The study will look at the immunological characteristics of COVID-19 patients and determine neutralizing antibodies against SARS-CoV-2 virus.
The immunogram (quantitative TBNK immunophenotipisation) will be performed by flow cytometry,
the antibody response will be determined by IVD ELISa.
Clinical biochemical and immunochemical (ECLIA) tests (including IL-6) will be performed on
Cobas analyzers. Hemogram with differential blood picture will be performed with a hematology
analyzer Sysmex XN 3100, examination of blood smears with CellaVision system or. microscope.
Coagulation tests will be performed on BCS XP analyzers.
An in-house system for the analysis of SARS-CoV-2 virus fusion inhibitors on human cells will
be used to detect the ability of antibodies from patients' serum to neutralize the virus and
thus potential protection against re-infection. The system is quantitative, meaning that the
titer of such antibodies could be determined, and thus the potential level of protection
would be evaluated.
Inclusion Criteria:
Provide written consent before being included in the essay.
Positive cases of COVID-19 (based on polymerase chain reaction or positive antigen test for
SARS-CoV-2).
Exclusion Criteria:
Patients who are unable to give consent or who are unable to follow up will be excluded.
University Clinic of Respiratory and Allergic Diseases Golnik
Golnik, Slovenia
Investigator: Peter Korošec, PhD
Contact: 4 25 69 432
peter.korosec@klinika-golnik.si
Investigator:
Peter Korošec, PhD
042569432 - +386
peter.korosec@klinika-golnik.si
Gregor Ostanek
42569500 - +386
gregor.ostanek@klinika-golnik.si
Peter Korošec, PhD, Principal Investigator
Head of the Laboratory for Clinical Immunology and Molecular Genetics